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Abstract
Background: Drug related problems (DRPs) are common among elderly patients who are discharged from the
hospital and are using several drugs for their chronic diseases. Examples of drug related problems are contra-
indications, interactions, adverse drug reactions and inefficacy of treatment. Causes of these problems include
prescription errors and non-compliance with treatment. The aim of this study is to examine the effect of
medication review and cognitive behaviour therapy of discharged patients by community pharmacists to minimize
the occurrence of drug related problems.
Methods/Design: A randomized controlled trial will be performed. Community pharmacists will be randomized
into a control group and an intervention group. 342 Patients, aged over 60 years, discharged from general and
academic hospitals, using five or more prescription drugs for their chronic disease will be asked by their pharmacy
to participate in the study.
Patients randomized to the control group will receive usual care according to the Dutch Pharmacy Standard. The
medication of patients randomised to the intervention group will be reviewed by the community pharmacist with
use of the national guidelines for the treatment of diseases, when patients are discharged from the hospital. The
Pharmaceutical Care network Europe Registration form will be used to record drug related problems. Trained phar-
macy technicians will counsel patients at home at baseline and at 1,3,6,9 and 12 months, using Cognitive Behaviour
Treatment according to the Theory of Planned Behaviour. The patient’s attitude towards medication and patient’s
adherence will be subject of the cognitive behaviour treatment. The counselling methods that will be used are moti-
vational interviewing and problem solving treatment. Patients adherence towards drug use will be determined with
use of the Medication Adherence Report Scale Questionnaire. There will be a follow-up of 12 months.
The two primary outcome measures are the difference in occurrence of DRPs between intervention and control
group and adherence with drug use. Secondary endpoints are attitude towards drug use, incidence of Re-
hospitalisations related to medicines, functional status of the patient, quality of life and the cost-effectiveness of
this intervention.
Discussion: Combining both medication review and Cognitive Behaviour Treatment may decrease DRPs and may
result in more compliance with drug use among patients discharged from the hospital and using 5 or more
chronic drugs.
Trial registration: Dutch Trial Register NTR1194
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Drug related problems (DRPs) are events or circum-
stances involving drug therapy that actually or poten-
tially interfere with desired health outcomes [1].
Examples of DRPs are contra-indications, interactions,
adverse drug reactions (ADR) and inefficacy of treat-
ment. Causes for these problems can be prescription
errors, non-compliance with treatment and the specific
effects of drugs in patients. Factors that increase the risk
of DRPs are polypharmacy, co-morbidity, aging, non-
adherence and lack of coordination between different
treating physicians.
An increased number of prescribed drugs (polyphar-
macy) strongly increase the risk of DRP. Runciman
found a correlation between increases in medication use
and rates of adverse drug reactions associated with hos-
pitalization [2]. Another recent review of studies of the
effect of polypharmacy on the health state of elderly
people has shown that multiple drug use is a strong pre-
dictor of hospitalisations, nursing home placement,
death, hypoglycaemia, fractures, impaired mobility,
pneumonia and malnutrition [3]. Furthermore, Leendert
et al suggest that elderly people have a higher risk of
hospitalisation caused by DRP, especially if they use
have 4 or more co-morbidity [4].
Elderly people >75 year seem at higher risk for hospi-
talisation caused by DRP [2]. A study conducted in the
Netherlands examined the occurrence of hospitalisations
that were related to medication. This study showed
12.793 acute hospital admissions per year of which 714
admissions were medication related and 332 of these
admissions were preventable. They calculated that
19.000 hospital admissions per year were related to
medication and were preventable [4]. Specific risk fac-
tors were the number of prescribing physicians [5] and
the number of diagnoses [6], the number and combina-
tion of several (inappropriate) drugs [6,7] and the use of
inappropriate drugs [8-11].
Non-adherence is another risk factor for the occur-
rence of DRP. Assuming that drugs have been pre-
scribed correctly, non-compliance may substantially
affect the efficacy of treatment or even enhance the risk
of side effects [12-14]. In the Dutch population 50% of
the patients were shown to discontinue the use of
chronic medication within one year after initiation. Dis-
continuation of chronic medication depended on the
type of chronic medication and occurred frequently
among patients who were using antihypertensive medi-
cation, cholesterol lowering drugs, anti-osteoporoses
drugs, anti-rheumatic medications and antidepressants
[15].
Hospitalisation can also be the cause of DRP. Hospita-
lisation and subsequent discharge are associated with
discontinuity of care [16]. At the point of discharge the
use of certain drugs may have been discontinued and
the doses of others changed while new medication may
have been added. In the Netherlands, pharmacists use a
computerized system to detect drug problems among
their patients. This system fails to detect all drug pro-
blems and does not provide information on problems
with medication use, which elderly patients may experi-
ence. In the present study, pharmacists will perform a
medication review on elderly patients discharged from
the hospital. This medication review is a structured, cri-
tical examination of patient’s medicines with the objec-
tive of reaching an agreement with the patient about
treatment, optimising the impact of medicines, minimis-
ing the number of medication-related problems and
reducing waste [17].
A systematic review conducted by Royal et al. con-
cluded that there was evidence showing that pharma-
cist-initiated interventions including a medication
review component are effective in reducing hospital
admissions by 36%. Several studies have shown that cog-
nitive behaviour treatment can be useful in improving
medication adherence among patients [18,19]. Patients
may benefit of changes in attitude to medication, result-
ing in increased compliance with drug use.
The present randomized controlled study aims to
improve pharmacotherapy by means of combining two
effective strategies including medication review and cog-
nitive behaviour treatment. To our knowledge, the effect
of combining both methods to minimize drug related
problems and improve compliance among elderly
patients discharged from the hospital has not been stu-
died previously.
Theoretical framework the cognitive behavioural
approach
Studies have shown that a change in patients attitude to
medications may enhance adherence to medications
[16-20]. Behavioural interventions may increase this
effect [16-20]. A behavioural model of medication
adherence is shown in figure 1. This model is based on
the Theory of Planned Behaviour and provides insight
into the factors that may determine adherence beha-
viour [18,19]. Patients gain ‘treatment experience’ once
they are exposed to a medical regimen. To enable
patients to adequately make informed choices about
their behaviour and to motivate themselves to execute
the behaviour correctly and at the right time, patients
must possess a basic level of understanding about their
illness. Health care professionals must communicate this
information in understandable and concrete language,
tailored to the needs of each specific patient [19]. The
most important concept used in the adherence model is
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recommendations. The Theory of Planned Behaviour
states that the intention to adhere is determined by the
subjective norm, the attitude and the perceived beha-
vioural control [18]. The subjective norm is what a per-
son thinks other people believe (s) he should do (e.g.
physicians or partners) and the motivation to comply
with these normative references. The subjective norm of
a patient can be changed through either changing the
patients perception of the norm, or through changing
the patients motivation to comply with this norm.
The attitude reflects salient beliefs about the perceived
outcomes of these behaviours (e.g. adherence leads to
better health than non-adherence) and the evaluations
of these outcomes (e.g. good health is essential for living
longer). It is important for the patient to realise that the
benefit of adhering to the medical regimen outweigh the
costs. It is therefore important that doctors and commu-
nity pharmacists explain to the patient what the benefits
are of medication adherence. The patient will then be
able to make his own informed choice about his medi-
cines and outweigh the costs of this behaviour.
The last component is the perceived behavioural con-
trol (PBC). The PBC has two components: self-efficacy
dealing with the perceived ease or difficulty of perform-
ing behaviour, such as feeling confident to always take
medication correctly in a private setting and controll-
ability the extent to which the behaviour is up to the
person. If a person has a demanding job it is sometimes
difficult to remember intake or have some privacy. To
optimize someone’s PBC, it is useful to separate
behaviour in small and simple steps and to facilitate the
behaviour where possible (for example: use dose organi-
zers) and plan the execution of the behaviour in a set-
ting in which the patient feels confident about correctly
performing the behaviour on a daily basis.
The outcome of the attitude, subjective norm and per-
ceived behaviour control is expressed in a behavioural
intention. This intention leads to accepting or refusing
adherence to the treatment as prescribed [19].
Medication review
Medication review is an intervention that can be used to
prevent the occurrence of DRP. Medication review
requires access to the patients notes, full record of pre-
scriptions and non-drug care and results from labora-
tory tests etc. The medicines used by the patient will be
reviewed in the context of the patients condition and
the perspective of the patient. In this process the patient
is involved as a full partner. This means listening to the
patient’s views and beliefs about their medicines, reach-
ing an honest understanding of their medicine taking
behaviour and taking full account of their preferences in
any decisions about treatment. Possible detected DRPs
are communicated with the prescriber, in order to find
a solution for these problems. Any changes made will
then be communicated with the patient.
Cognitive behaviour treatment
To increase concordance with drug use, according to
our theoretical framework, we have developed a com-
bined intervention with motivational interviewing (MI)
Figure 1 Model for Medication Adherence: theory of planned behaviour.
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increase patient’s motivation towards concordance with
medication prescription [21]. When patients experience
barriers with medication use, PST will be used in order
to give patients the tools to overcome these barriers
[22].
Motivational interviewing
Motivational interviewing is a client-oriented counselling
method that is shown to be effective in improving
health behaviour [21]. Increasing the intrinsic motiva-
tion of patients can then lead to a positive behavioural
change. During the counselling sessions the therapist
does not take an expert role but rather a role as a part-
ner. MI includes 5 counselling techniques aimed at
helping patients resolve ambivalence about health beha-
viour: (1) expressing empathy; (2) developing discre-
pancy; (3) avoiding argument (4) rolling with resistance;
and (5) supporting self-efficacy [21]. When patients are
motivated to change their health behaviour, the next
step is to increase their self-management towards this
behaviour by using PST.
Problem solving treatment
This intervention increases the ability of patients to
solve their problems in a structured way and improve
their confidence in dealing with future problems. The
treatment aims to give patients the tools to overcome
barriers in order to stimulate structural healthy beha-
viour. During the treatment session there is an active
collaboration between the patient and the pharmacist, in
which the patient takes an active role in the planning of
his treatment [23]. PST can be considered as a series of
7 stages [22].
1. Explanation of the intervention and its rationale
2. Definition and breaking down of the problem
3. Establishing achievable goals for the problem reso-
lution. Achieve goals are SMART goals: Specific,
Measurable, Achievable, Relevant, Timed
4. Generating multiple possible solutions
5. Evaluating and choosing the solution
6. Implementing the preferred solution
7. Evaluating the outcome
Objectives of this study
The objective of this study is to investigate the effects of
a multifaceted intervention, existing of medication
review and a CBT intervention for medication adher-
ence, on the occurrence of DRP in elderly patients of 60
year and older discharged from the hospital using five
or more drugs. The hypothesis of this study is that this
multifaceted intervention will reduce the occurrence of
DRP and improve compliance. The secondary objectives
are to evaluate the effect of the intervention on: attitude
to drugs, incidence of Re-hospitalisations related to
medicines, functional status of the patient, quality of
life. Moreover, the cost-effectiveness of this intervention
will be analysed.
Methods/Design
Design of the study
The study is designed as a randomized, controlled,
intervention study involving 342 patients with a follow-
up of one year. The intervention will be performed by
community pharmacists. A flow-chart of the study is
shown in Figure 2.
The Medical Ethics Committee of the VU University
medical enter in Amsterdam approved the study design,
protocols, information letters and informed consent form.
Setting
The trial will be conducted in 23 community pharmacists
in Amsterdam, Amstelveen, Hoofddorp and Diemen, the
Netherlands. The medication review will be performed
by a pharmacist in close collaboration with the general
practitioner (GP). The patients will be counseled at home
or in the pharmacy by a pharmacy technician.
Study Population
A total of 342 patients discharged from any department,
except oncology and psychiatry, from any general and
academic hospital in Amsterdam, Amstelveen, Hoofd-
dorp and Diemen will be enrolled into the study.
Patients 60 years and older, using five or more prescrip-
tion-only chronic drugs when admitted to the hospital
are considered eligible to participate into the study. The
pharmacists will evaluate whether the patient uses 5 or
more chronic drugs. Furthermore, to participate, the
patients have to give written informed consent.
Treatment allocation
Ten Pharmacotherapeutic Audit Meetings (PTAMs) will
participate in the study. In the Netherlands general
practitioners and pharmacistsa r eo r g a n i z e di nP T A M s .
Within a PTAM pharmacists are randomized as a con-
trol or intervention pharmacist.
Study procedures
Intervention group
Medication review The medication of patients in the
intervention group will be reviewed by the community
pharmacist using the full record of prescription only drugs
which were dispensed by the patients’ pharmacy and the
patients medication evaluation profile. This profile shows
when the patients has obtained his medication from the
pharmacy. The GP will be consulted by telephone for
details about indications for drugs and results from labora-
tory tests. When prescribed by a medical specialist, details
about the indication for the drug will be obtained from
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pharmacist. The National guidelines for treatment of dis-
eases will be used by community pharmacists as a method
for performing medication review.
The Pharmaceutical care network Europe DRP-score
form will be used to record drug problems. Each drug
will be evaluated on adverse reactions, drug choice pro-
blems, dosing problems, drug use problems, drug-inter-
actions or other problems. Causes for drug related
problems will be assessed and interventions will be
made. During the medication review the patient will
be involved as a full partner. Any changes made will be
communicated with the patient. This method for medi-
cation review will be pilot tested before use.
The occurrence of drug related problems will be dis-
cussed with the GP. The result may be an adaptation of
the drug regimen. The medication review will take 10-
30 minutes per patient and will depend on the complex-
ity of the medication regimen and problems detected.
Cognitive behaviour treatment Patients randomised to
the intervention group will also receive cognitive beha-
viour treatment (CBT) at baseline and 1, 3, 6, 9 and 12
months by a pharmacy technician, with help of a struc-
tured interview protocol and with use of communication
and motivational interviewing skills at home or in the
pharmacy. The first session will be within one week of
inclusion in order not to delay participant program
admission. During these sessions the result of the medi-
cation review will be discussed with the patient. The
patient will be informed about the effects, side effects
and use of the drugs. Patients will be counselled accord-
ing to the motivational interviewing principle to sustain
or improve their drug adherence. The patients under-
standing of his or hers condition and its treatment are
considered when appropriate. If possible, home supplies
of drugs are checked and rationalised at each visit. All
patients receive a written outline of their drug regimen.
Cancelled and redundant drugs are taken in. During the
session, over the counter remedies will be included in
the medication review. All sessions are done by pharma-
cist technicians with help of a structured protocol. The
patient visit will take 30-60 minutes.
Training course pharmacists All participating interven-
tion pharmacists will participate in a one day medication
review training course. During this training session the
background of medication review will be explained. The
use of Medication Evaluation Profiles will be explained.
Furthermore, the way the PCNE DRP-score form should
be used will be explained.
To pilot test the interrater variability of the PCNE
DRP-score form and the efficacy of the medication
review training all participating pharmacists (controls
and intervention pharmacists) will receive 5 medication
overviews of test-patients with additional information
about clinical notes approximately three months before
the medication review training session. The results of
the medication reviews will be evaluated by a specialist
in medication review.
When intervention pharmacists have completed the
training course in medication review, all pharmacists
(control and interventions) will be asked to review five
new test-patients. The intervention pharmacists are
expected to detect more DRPs afterwards than control
pharmacists who did not receive a special training in
medication review. The results of the medication
r e v i e w sw i l lb ee v a l u a t e db yt h es a m es p e c i a l i s ta s
before.
Training pharmacy technicians All intervention tech-
nicians will participate in a two days training course of
motivational interviewing and a one day course of pro-
blem solving treatment. During these training sessions
pharmacy technicians will be lectured about communi-
cation skills such as Motivational interviewing and Pro-
blem solving treatment skills by a specialized
psychologist on this subject. In addition pharmacy tech-
nicians will receive coaching on the job. Video tapes of
interviews with patients will then be recorded and
reviewed by two independent researchers using the
Motivational Interviewing Treatment Integrity Code
score method to evaluate the quality of the motivational
interviewing skills of the pharmacy technicians.
Pharmacotherapeutic Audit Meetings (PTAM) In
addition, to improve the intervention and its perfor-
mance, the intervention will be discussed in Pharma-
cotherapeutic Audit Meetings (PTAM). At PTAM
meetings agreements are made to improve the pharma-
cotherapeutic care provided. A PTAM-group generally
consists of 2 to 6 pharmacists from 2 to 3 pharmacies
and 6 to 10 general practitioners. During this study
three PTAM sessions are organized. The first to discuss
t h ei n t e r v e n t i o n .T h es e c o n dt om a k et h ea g r e e m e n t s
and the third PTAM sessions are used to evaluate, the
procedure.
Control Group
Patients of control pharmacists will receive usual care
according to the Dutch Pharmacy Standard (Table 1).
Furthermore, patients are visited once by a pharmacy
technician and asked about possible drug related pro-
blems. These problems will be registered for scientific
use only.
Outcome Measures
Primary outcome measures
Using a checklist including common drug problems, the
prevalence of DRP in patients of control and interven-
tion pharmacists will be determined at base-line and at
12 months by a team of independent clinical pharmacol-
ogists. The identification of drug problems by
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structured interview of the patient and the medication
overview of the patient registered in the pharmacy infor-
mation and administration system.
Adherence with drug treatment
The 5-item self-report Medication Adherence Rating
Scale (MARS) will be used to assess medication adher-
ence [24].
Secondary outcome measures
Incidence of Re-hospitalization The total incidence of
hospital re-admissions possibly related to medicine dur-
ing the study period is measured. The incidence of hos-
pital admissions will be derived from general
practitioners medical record and determined by self
report. The relation to drugs will be derived using a list
of selection criteria. Hospital admissions will be classi-
fied as related to drugs if:
▪ It is explicitly clarified in the medical notes that
the admission is drug related. The specialist of the
patient will be consulted to clarify the relation to
drugs.
▪ The patients’ physician, when asked, indicates that
the admission was drug related.
▪ To classify the causality of the hospital admission
to the drug, the Naranjo algorithm will be used. The
Naranjo algorithm or Naranjo Scale is a question-
naire designed by Naranjo et al for determining the
likelihood of whether an ADR is actually due to the
drug rather than the result of other factors [25]. The
causality will be determined by the project leader.
All participating patients are asked to complete 3 vali-
dated questionnaires during the research year. The first
questionnaire will be sent to the patients one week
before the first counselling visit of the pharmacist. The
second questionnaire will be sent at 6 months, the third
questionnaire will be sent at 12 months. It will
take approximately 30 minutes to complete one
questionnaire.
Beliefs about Medicines will be assessed by questionnaire
- Beliefs about Medicines Questionnaire (BMQ) [26,27].
- Attitude towards prescribed medicine [28].
Functional status of the patient
Functional status of the patient will be determined by
examining the following dimensions: physical function-
ing, role limitation due to physical health problems,
bodily pain, general health perceptions, vitality, social
functioning and general mental health. These dimen-
sions will be determined using the RAND-36 question-
naire [29].
Patient satisfaction about prescribed medicines
Patients satisfaction will be determined using the Satis-
faction with Information about Medicines questionnaire
(SIMS) [30].
Quality of life
Quality of life: mobility, self- care, main activity (work,
study, housework, leisure), social relationships, pain,
mood will be assessed using the EuroQol [31].
Costs effectiveness
Costs will be registered by the pharmacists in terms of
time and material spent on the counselling of patients.
Health care costs made by the patient will be assessed
from a societal perspective using monthly costs calen-
dars in which direct and indirect costs will be prospec-
tively determined by the patient. The following costs
will be included in the calendars.
▪ Visits to a General Practitioner (including home
visits)
▪ Visits to a medical specialist
▪ Visits to a physiotherapist
▪ Hospitalisations or admission to a nursing home
▪ Informal care (from neighbours, family or friends)
▪ Alternative medical treatment.
Costs of prescription-only medication use will be
derived from the pharmacy system.
Sample size
The primary outcome measure is the result of the medi-
cation review and patient counselling on the occurrence
of DRPs. Based on previous studies it is estimated that
the percentage of DRP in the patients of control
Table 1 Usual care, according to the Dutch Pharmacy Standard
1 Preceding the release check, prescriptions are routinely checked for drug interactions and contra-indications by the PAIS.
2 Discharge medication is delivered at the patients’ home or is picked up by the patient or carer in the pharmacy.
3 Drugs are routinely delivered with a drug information leaflet but patients often are also handed supplementary personalized PAIS-generated
information letters on newly prescribed drugs.
4 When the discharge medication is collected from the pharmacy, the patient or carer is also provided with additional oral information about
newly prescribed drugs.
This includes an explanation of the drugs’ actions, their use and of possible side effects.
First edition of 1996. The current (2nd) edition was introduced in 2006 (KNMP, The Hague).
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reduces the number of preventable DRP with one third
(33%). With a type 1 error of 0.05, a power of 80%, and
a ration of one between both groups of patients, multile-
vel randomisation resulting in a loss of power of 15%, a
total of 342 patients is needed to show a statistically sig-
nificant difference. The estimated number of patients
fulfilling the criteria and willing to participate is 4 per
pharmacy per month. With an actual recruitment time
of 6 months, and about 20 participating pharmacies, the
number of 342 patients will be achieved.
Analyses
Descriptive statistics (means ± SD or median and inter-
quartile range in case of a skewed distribution) will be
used to describe the whole study sample with regard to
demographics, drug use and reason for previous hospital
admission. The analyses will be conducted according to
the intention-to-treat principle. To assess the impact of
the intervention, multilevel linear and logistic regression
analyses will be conducted to study differences in out-
come measures between patients of the intervention and
control pharmacies. Using multilevel analyses enables
taking clustering of observations of participants receiv-
ing care from the same GP and for repeated measure-
ments within one subject in account. Differences in
changes between groups are measured with 95% confi-
dence intervals. We will adjust data for possible con-
founders and effect modifiers (age, sex, ethnicity, level
of education). Separate analyses of effect modifiers and
mediators will be conducted in order to gain a better
understanding which subgroups benefit most from the
intervention. Confidence intervals of differences in costs
between groups will be estimated using bootstrapping
methods. (Bootstrapping statistics is a general method
for performing statistical analyses without making strong
parametric assumptions [32].
Discussion
This article presents a description of a RCT, which aims
to investigate whether a multifaceted intervention by the
community pharmacist existing of medication review
and CBT to increase drug adherence after discharge
from the hospital, is effective in reducing DRPs among
elderly patients of 60 years and older using five or more
prescript drugs for a chronic disease. The present paper
will provide other researchers working on this subject,
GPs, pharmacists, medical specialists, other health care
providers and policy makers an overview of the RCT.
This enables them to critically review the methodologi-
cal quality, the background theory and the practical
issues of the RCT. Previous studies have shown that
pharmacist initiated interventions are effective in redu-
cing DRPs [33,34]. To our knowledge this is the first
study that will combine two strategies: medication
review and CBT to reduce the occurrence of DRPs
among patients who are at higher risk to these pro-
blems. Studies have shown that medication review is an
effective method in decreasing the occurrence of DRPs
[34]. Most studies have studied the effect of medication
review on patients in all age categories on the occur-
rence of drug problems. In this study we will determine
the effect of medication review on the occurrence of
DRPs among elderly patients who are discharged from
the hospital. This has not yet been studied before.
Furthermore, we expect that patient CBT based on
motivational interviewing and problem solving treatment
will increase or sustain patient’s drug adherence after
hospital discharge and therefore lowers the risk of hav-
ing a DRPs and re-hospitalisation.
There are several practical limitations associated with
performing medication review. Detecting and solving
drug related problems by health care workers such as
community pharmacists is a time consuming process
[35]. In order to make any changes in the drug regimen,
the pharmacist has to contact the general practitioner
first, which is time consuming. Furthermore, community
pharmacists have to communicate the changes that are
made with their patients. Because of their busy daily
schedules, it may be possible that pharmacists do not
find that medication review has a priority. Another
major limitation is the possible bias in the detection and
solving of DRPs by the different community pharmacists
since all pharmacists have different experiences in per-
forming a medication review. Some pharmacists will
therefore identify more or less drug related problems
than others, depending on the limited time. In addition,
another limitation of the intervention is that the perfor-
mance of CBT might differ between pharmacy techni-
cians because of the interview skills they have. It is
therefore difficult to decide whether all patients receive
the same therapy sessions. We will try to reduce the dif-
ferences between the pharmacy technicians, by using a
structured interview protocol and motivational inter-
viewing and problem solving treatment courses. A
major strength is by combining medication review and
CBT sessions can lead to a possible improvement of
detection of drug related problems. The CBT sessions
with patients discharged from the hospital will be help-
f u li nd e t e c t i n gd r u gp r o b l e m ss u c ha ss i d ee f f e c t sa n d
non-compliance, and thus lead to a better communica-
tion between the community pharmacy and patient.
A limitation of the study design is that there is no lit-
erature available that describes an evidence based
method that can be used by pharmacists to report the
quality of the pharmacotherapy or how to detect and
solve drug related problems. However, we will apply in
this study a method of prescription problems which we
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study design is that it is a RCT.
The inclusion of the patients has been performed
between in January 2008 and March 2009. Duration of
the study will be one year. If this study has a positive
effect in reducing the occurrence of drug related pro-
blems, it can be implemented as within a community
pharmacy. This service can be specially implemented for
patients discharged from the hospital, in order to mini-
mize the occurrence of DRPs.
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